bluebird bio (BLUE) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

BLUE Stock Forecast

bluebird bio stock forecast is as follows: an average price target of $14.13 (represents a 4643.20% upside from BLUE’s last price of $0.30) and a rating consensus of 'Hold', based on 4 wall street analysts offering a 1-year stock forecast.

BLUE Price Target

The average price target for bluebird bio (BLUE) is $14.13 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $25.00 to $5.00. This represents a potential 4643.20% upside from BLUE's last price of $0.30.

BLUE Analyst Ratings

Hold

According to 4 Wall Street analysts, bluebird bio's rating consensus is 'Hold'. The analyst rating breakdown for BLUE stock is 0 'Strong Buy' (0.00%), 1 'Buy' (25.00%), 2 'Hold' (50.00%), 1 'Sell' (25.00%), and 0 'Strong Sell' (0.00%).

bluebird bio Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Aug 22, 2022	Gena Wang	Barclays	$5.00	$5.83	-14.16%	1578.42%
Mar 07, 2022	David Nierengarten	Wedbush	$10.00	$4.45	124.72%	3256.83%
Nov 19, 2021	Cory Kasimov	J.P. Morgan	$14.00	$10.70	30.84%	4599.56%
Nov 12, 2021	Zhiqiang Shu	Berenberg Bank	$11.00	$11.68	-5.82%	3592.51%
Nov 08, 2021	Salveen Richter	Goldman Sachs	$10.00	$10.70	-6.54%	3256.83%
Sep 13, 2021	Joshua Schimmer	Evercore ISI	$25.00	$11.84	111.15%	8292.08%
Aug 10, 2021	John Newman	Canaccord Genuity	$20.00	$12.97	54.20%	6613.66%
Aug 09, 2021	Benjamin Burnett	Stifel Nicolaus	$18.00	$11.76	53.06%	5942.30%

Row per page

Go to

The latest bluebird bio stock forecast, released on Aug 22, 2022 by Gena Wang from Barclays, set a price target of $5.00, which represents a -14.16% decrease from the stock price at the time of the forecast ($5.83), and a 1578.42% increase from BLUE last price ($0.30).

bluebird bio Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	-
Avg Price Target	-	-	-
Last Closing Price	$0.30	$0.30	$0.30
Upside/Downside	-100.00%	-100.00%	-100.00%

In the current month, the average price target of bluebird bio stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to bluebird bio's last price of $0.30. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Sep 25, 2024	RBC Capital	Underperform	Underperform	Hold
Sep 25, 2024	Wells Fargo	Sector Perform	Sector Perform	Hold
Aug 15, 2024	RBC Capital	Sector Perform	Sector Perform	Hold
Aug 15, 2024	Barclays	Underperform	Underperform	Hold
Aug 15, 2024	Oppenheimer	Perform	Perform	Hold
Mar 27, 2024	Wells Fargo	Sector Perform	Sector Perform	Hold
Mar 27, 2024	Wedbush	Underperform	Underperform	Hold
Dec 15, 2023	Wells Fargo	Equal-Weight	Equal-Weight	Hold
Jul 19, 2023	Wedbush	Neutral	Buy	Upgrade
Jun 01, 2023	Barclays	Equal-Weight	Overweight	Upgrade

Row per page

Go to

bluebird bio's last stock rating was published by RBC Capital on Sep 25, 2024. The company gave BLUE a "Underperform" rating, the same as its previous rate.

bluebird bio Financial Forecast

bluebird bio Revenue Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	$12.39M	$6.89M	$2.38M	$62.00K	$71.00K	$1.52M	$1.95M	$-39.28M	$22.68M	$7.47M	$12.79M	$10.71M	$19.27M	$198.89M	$21.86M	$10.00M	$8.91M
Avg Forecast	$115.74M	$108.53M	$94.95M	$90.22M	$85.26M	$78.52M	$58.83M	$37.72M	$26.08M	$18.05M	$24.25M	$19.26M	$16.78M	$13.56M	$11.30M	$6.52M	$1.05M	$1.07M	$824.17K	$187.50K	$5.08M	$37.21M	$16.28M	$11.55M	$14.65M	$24.32M	$76.46M	$7.58M	$9.17M	$11.38M
High Forecast	$141.25M	$132.45M	$115.89M	$110.11M	$104.06M	$95.83M	$71.80M	$43.94M	$28.08M	$22.03M	$24.25M	$19.59M	$20.64M	$13.60M	$13.79M	$7.96M	$1.28M	$1.07M	$824.17K	$187.50K	$5.08M	$37.21M	$16.28M	$11.55M	$14.65M	$24.32M	$76.46M	$7.58M	$9.17M	$11.38M
Low Forecast	$88.12M	$82.63M	$72.29M	$68.69M	$64.92M	$59.78M	$44.79M	$34.26M	$24.07M	$13.74M	$24.25M	$18.93M	$11.63M	$13.52M	$8.61M	$4.97M	$795.74K	$1.07M	$824.17K	$187.50K	$5.08M	$37.21M	$16.28M	$11.55M	$14.65M	$24.32M	$76.46M	$7.58M	$9.17M	$11.38M
# Analysts	2	2	2	2	1	1	1	4	4	2	3	4	7	5	6	3	2	2	2	2	3	4	5	6	9	8	7	6	5	5
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	0.91%	0.61%	0.36%	0.06%	0.07%	1.84%	10.37%	-7.73%	0.61%	0.46%	1.11%	0.73%	0.79%	2.60%	2.88%	1.09%	0.78%

bluebird bio's average Quarter revenue forecast for Dec 23 based on 7 analysts is $16.78M, with a low forecast of $11.63M, and a high forecast of $20.64M. BLUE's average Quarter revenue forecast represents a 35.44% increase compared to the company's last Quarter revenue of $12.39M (Sep 23).

bluebird bio EBITDA Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	2	2	2	2	1	1	1	4	4	2	3	4	7	5	6	3	2	2	2	2	3	4	5	6	9	8	7	6	5	5
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	$-84.73M	$-85.30M	$-84.49M	$25.43M	$-88.18M	$-92.78M	$-119.33M	$-153.24M	$-210.63M	$-235.05M	$-199.67M	$-193.36M	$-187.50M	$-13.97M	$-192.28M	$-211.23M	$-193.33M
Avg Forecast	$-115.74M	$-108.53M	$-94.95M	$-90.22M	$-85.26M	$-78.52M	$-58.83M	$-37.72M	$-26.08M	$-18.05M	$-24.25M	$-85.33M	$-16.78M	$-13.56M	$-11.30M	$-91.26M	$-206.14M	$-1.07M	$-824.17K	$-97.61M	$-5.08M	$-37.21M	$-16.28M	$-195.69M	$-14.65M	$-24.32M	$-76.46M	$-210.02M	$-9.17M	$-11.38M
High Forecast	$-88.12M	$-82.63M	$-72.29M	$-68.69M	$-64.92M	$-59.78M	$-44.79M	$-34.26M	$-24.07M	$-13.74M	$-24.25M	$-68.26M	$-11.63M	$-13.52M	$-8.61M	$-73.01M	$-164.91M	$-1.07M	$-824.17K	$-78.09M	$-5.08M	$-37.21M	$-16.28M	$-156.55M	$-14.65M	$-24.32M	$-76.46M	$-168.02M	$-9.17M	$-11.38M
Low Forecast	$-141.25M	$-132.45M	$-115.89M	$-110.11M	$-104.06M	$-95.83M	$-71.80M	$-43.94M	$-28.08M	$-22.03M	$-24.25M	$-102.40M	$-20.64M	$-13.60M	$-13.79M	$-109.52M	$-247.37M	$-1.07M	$-824.17K	$-117.13M	$-5.08M	$-37.21M	$-16.28M	$-234.83M	$-14.65M	$-24.32M	$-76.46M	$-252.03M	$-9.17M	$-11.38M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	6.25%	7.55%	0.93%	-0.12%	82.09%	112.57%	1.22%	30.15%	5.66%	14.44%	1.02%	13.20%	7.71%	0.18%	0.92%	23.04%	16.99%

3 analysts predict BLUE's average Quarter EBITDA for Mar 23 to be $-91.26M, with a high of $-73.01M and a low of $-109.52M. This is -458.81% lower than bluebird bio's previous annual EBITDA (Dec 22) of $25.43M.

bluebird bio Net Income Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	2	2	2	2	1	1	1	4	4	2	3	4	7	5	6	3	2	2	2	2	3	4	5	6	9	8	7	6	5	5
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	-	$-71.73M	$-72.91M	$34.04M	$32.23M	$-76.52M	$-92.88M	$-123.96M	$101.69M	$-216.82M	$-241.70M	$-205.81M	$-199.87M	$-194.75M	$-21.46M	$-202.61M	$-223.35M	$-206.03M
Avg Forecast	$17.40M	$14.93M	$9.69M	$7.43M	$3.49M	$-1.94M	$-17.13M	$-34.26M	$-58.38M	$-70.60M	$-80.79M	$-86.05M	$-127.31M	$-129.64M	$-136.73M	$-92.03M	$-213.08M	$-216.41M	$-251.19M	$-98.42M	$-381.68M	$-307.48M	$-409.97M	$-201.71M	$-372.44M	$-382.72M	$-301.73M	$-221.31M	$-475.02M	$-446.36M
High Forecast	$22.39M	$19.21M	$12.47M	$9.55M	$4.49M	$-1.34M	$-11.81M	$-21.08M	$-44.37M	$-48.70M	$-55.72M	$-68.84M	$33.50M	$-89.42M	$-94.31M	$-73.62M	$-170.47M	$-216.41M	$-251.19M	$-78.74M	$-381.68M	$-307.48M	$-409.97M	$-161.36M	$-372.44M	$-382.72M	$-301.73M	$-177.04M	$-475.02M	$-446.36M
Low Forecast	$12.00M	$10.30M	$6.69M	$5.12M	$2.41M	$-2.49M	$-22.04M	$-47.43M	$-77.07M	$-90.83M	$-103.94M	$-103.25M	$-218.88M	$-166.79M	$-175.92M	$-110.43M	$-255.70M	$-216.41M	$-251.19M	$-118.11M	$-381.68M	$-307.48M	$-409.97M	$-242.05M	$-372.44M	$-382.72M	$-301.73M	$-265.57M	$-475.02M	$-446.36M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	0.55%	0.53%	-0.37%	-0.15%	0.35%	0.37%	1.26%	-0.27%	0.71%	0.59%	1.02%	0.54%	0.51%	0.07%	0.92%	0.47%	0.46%

bluebird bio's average Quarter net income forecast for Jun 23 is $-136.73M, with a range of $-175.92M to $-94.31M. BLUE's average Quarter net income forecast represents a -501.65% decrease compared to the company's last Quarter net income of $34.04M (Mar 23).

bluebird bio SG&A Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	2	2	2	2	1	1	1	4	4	2	3	4	7	5	6	3	2	2	2	2	3	4	5	6	9	8	7	6	5	5
SG&A	-	-	-	-	-	-	-	-	-	-	-	-	-	$40.70M	$40.35M	$37.35M	$30.71M	$33.40M	$36.69M	$36.11M	$-19.74M	$68.28M	$78.58M	$86.87M	$76.97M	$68.05M	$68.63M	$73.25M	$76.20M	$66.25M
Avg Forecast	$2.51B	$2.35B	$2.06B	$1.95B	$1.85B	$1.70B	$1.27B	$816.53M	$564.48M	$390.73M	$524.98M	$416.96M	$363.29M	$293.52M	$244.66M	$141.23M	$22.62M	$23.25M	$17.84M	$4.06M	$110.03M	$805.36M	$352.41M	$249.99M	$317.17M	$526.51M	$1.66B	$164.07M	$198.49M	$246.30M
High Forecast	$3.06B	$2.87B	$2.51B	$2.38B	$2.25B	$2.07B	$1.55B	$951.14M	$607.91M	$476.86M	$524.99M	$424.13M	$446.83M	$294.41M	$298.59M	$172.37M	$27.61M	$23.25M	$17.84M	$4.06M	$110.03M	$805.36M	$352.41M	$249.99M	$317.17M	$526.51M	$1.66B	$164.07M	$198.49M	$246.30M
Low Forecast	$1.91B	$1.79B	$1.56B	$1.49B	$1.41B	$1.29B	$969.48M	$741.56M	$521.06M	$297.48M	$524.98M	$409.78M	$251.68M	$292.64M	$186.27M	$107.53M	$17.22M	$23.25M	$17.84M	$4.06M	$110.03M	$805.36M	$352.41M	$249.99M	$317.17M	$526.51M	$1.66B	$164.07M	$198.49M	$246.30M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	0.14%	0.16%	0.26%	1.36%	1.44%	2.06%	8.90%	-0.18%	0.08%	0.22%	0.35%	0.24%	0.13%	0.04%	0.45%	0.38%	0.27%

bluebird bio's average Quarter SG&A projection for Dec 23 is $363.29M, based on 7 Wall Street analysts, with a range of $251.68M to $446.83M. The forecast indicates a 792.53% rise compared to BLUE last annual SG&A of $40.70M (Sep 23).

bluebird bio EPS Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	2	2	2	2	1	1	1	4	4	2	3	4	7	5	6	3	2	2	2	2	3	4	5	6	9	8	7	6	5	5
EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	$-0.66	$-0.67	$0.33	$0.38	$-0.94	$-1.26	$-1.68	$1.40	$-3.16	$-3.58	$-3.07	$-3.01	$-2.94	$-0.36	$-3.64	$-4.04	$-3.73
Avg Forecast	$0.09	$0.08	$0.05	$0.04	$0.02	$-0.01	$-0.09	$-0.18	$-0.30	$-0.36	$-0.42	$-0.44	$-0.66	$-0.67	$-0.71	$-0.37	$-0.33	$-1.12	$-1.30	$-1.45	$-1.97	$-1.59	$-2.12	$-1.95	$-1.92	$-1.98	$-1.56	$-2.62	$-2.45	$-2.30
High Forecast	$0.12	$0.10	$0.06	$0.05	$0.02	$-0.01	$-0.06	$-0.11	$-0.23	$-0.25	$-0.29	$-0.30	$0.17	$-0.46	$-0.49	$-0.25	$-0.23	$-1.12	$-1.30	$-1.45	$-1.97	$-1.59	$-2.12	$-1.95	$-1.92	$-1.98	$-1.56	$-2.62	$-2.45	$-2.30
Low Forecast	$0.06	$0.05	$0.03	$0.03	$0.01	$-0.01	$-0.11	$-0.24	$-0.40	$-0.47	$-0.54	$-0.57	$-1.13	$-0.86	$-0.91	$-0.48	$-0.42	$-1.12	$-1.30	$-1.45	$-1.97	$-1.59	$-2.12	$-1.95	$-1.92	$-1.98	$-1.56	$-2.62	$-2.45	$-2.30
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	0.99%	0.95%	-0.89%	-1.16%	0.84%	0.97%	1.16%	-0.71%	1.99%	1.69%	1.57%	1.57%	1.49%	0.23%	1.39%	1.65%	1.62%

According to 6 Wall Street analysts, bluebird bio's projected average Quarter EPS for Jun 23 is $-0.71, with a low estimate of $-0.91 and a high estimate of $-0.49. This represents a -313.70% decrease compared to BLUE previous annual EPS of $0.33 (Mar 23).

bluebird bio Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
HEPA	Hepion Pharmaceuticals	$0.69	$70.00	10044.93%	Buy
BLUE	bluebird bio	$0.30	$14.13	4610.00%	Hold
CVAC	CureVac	$2.56	$29.00	1032.81%	Buy
KPTI	Karyopharm Therapeutics	$0.78	$7.33	839.74%	Buy
ZNTL	Zentalis Pharmaceuticals	$3.18	$21.86	587.42%	Buy
VIR	Vir Bio	$6.95	$26.60	282.73%	Buy
VKTX	Viking Therapeutics	$51.63	$102.40	98.33%	Buy
YMAB	Y-mAbs Therapeutics	$10.10	$20.00	98.02%	Buy
SRPT	Sarepta Therapeutics	$110.50	$169.06	53.00%	Buy
MRSN	Mersana Therapeutics	$1.98	$3.00	51.52%	Buy
TVTX	Travere Therapeutics	$18.26	$21.75	19.11%	Buy
PTCT	PTC Therapeutics	$42.89	$46.50	8.42%	Hold
KRYS	Krystal Biotech	$182.29	$191.00	4.78%	Buy
MDGL	Madrigal Pharmaceuticals	$329.24	$315.75	-4.10%	Buy
AGIO	Agios Pharmaceuticals	$55.54	$48.00	-13.58%	Buy

BLUE Forecast FAQ

Is bluebird bio a good buy?

No, according to 4 Wall Street analysts, bluebird bio (BLUE) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 25.00% of BLUE's total ratings.

What is BLUE's price target?

bluebird bio (BLUE) average price target is $14.13 with a range of $5 to $25, implying a 4643.20% from its last price of $0.298. The data is based on 4 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will bluebird bio stock go up soon?

According to Wall Street analysts' prediction for BLUE stock, the company can go up by 4643.20% (from the last price of $0.298 to the average price target of $14.13), up by 8292.08% based on the highest stock price target, and up by 1578.42% based on the lowest stock price target.

Can bluebird bio stock reach $0?

BLUE's average twelve months analyst stock price target of $14.13 supports the claim that bluebird bio can reach $0 in the near future.

What are bluebird bio's analysts' financial forecasts?

bluebird bio's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $260.34M (high $315.63M, low $203.75M), average EBITDA is $-260M (high $-204M, low $-316M), average net income is $-49.831M (high $-29.741M, low $-69.553M), average SG&A $5.64B (high $6.83B, low $4.41B), and average EPS is $-0.257 (high $-0.153, low $-0.359). BLUE's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $409.44M (high $499.7M, low $311.73M), average EBITDA is $-409M (high $-312M, low $-500M), average net income is $49.45M (high $63.62M, low $34.11M), average SG&A $8.86B (high $10.82B, low $6.75B), and average EPS is $0.255 (high $0.328, low $0.176).

Did the BLUE's actual financial results beat the analysts' financial forecasts?

Based on bluebird bio's last annual report (Dec 2022), the company's revenue was $3.6M, beating the average analysts forecast of $3.13M by 14.88%. Apple's EBITDA was $-277M, missing the average prediction of $-306M by -9.30%. The company's net income was $-267M, missing the average estimation of $-779M by -65.78%. Apple's SG&A was $136.91M, beating the average forecast of $67.77M by 102.01%. Lastly, the company's EPS was $-3.39, missing the average prediction of $-4.188 by -19.05%. In terms of the last quarterly report (Sep 2023), bluebird bio's revenue was $12.39M, missing the average analysts' forecast of $13.56M by -8.62%. The company's EBITDA was $-84.729M, beating the average prediction of $-13.56M by 524.83%. bluebird bio's net income was $-71.731M, missing the average estimation of $-130M by -44.67%. The company's SG&A was $40.7M, missing the average forecast of $293.52M by -86.13%. Lastly, the company's EPS was $-0.66, missing the average prediction of $-0.669 by -1.29%